Sintx Technologies (NASDAQ:SINT) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Sintx Technologies (NASDAQ:SINT) in a research note released on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $10.00 price target on the stock.

SINT has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sintx Technologies in a research report on Thursday, January 22nd. Ascendiant Capital Markets lowered their target price on Sintx Technologies from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $11.00.

Sintx Technologies Price Performance

Shares of Sintx Technologies stock opened at $2.87 on Monday. The firm has a market cap of $11.82 million, a price-to-earnings ratio of -0.51 and a beta of 0.66. The stock’s 50-day moving average is $2.78 and its 200-day moving average is $3.36. Sintx Technologies has a one year low of $1.71 and a one year high of $6.78.

Institutional Trading of Sintx Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of SINT. Virtus Wealth Solutions LLC acquired a new stake in shares of Sintx Technologies in the third quarter valued at about $388,000. Geode Capital Management LLC increased its position in Sintx Technologies by 53.4% during the fourth quarter. Geode Capital Management LLC now owns 26,624 shares of the company’s stock worth $103,000 after buying an additional 9,265 shares during the last quarter. Finally, Veracity Capital LLC increased its position in Sintx Technologies by 10.3% during the third quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after buying an additional 7,464 shares during the last quarter. Institutional investors and hedge funds own 18.38% of the company’s stock.

About Sintx Technologies

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.